(Q35626856)

9 August 2017

1 reference

title

Population genetic screening programmes: principles, techniques, practices, and policies (English)

1 reference

9 August 2017

0 references

4

Ségolène Aymé

1 reference

9 August 2017

1

Béatrice Godard

1 reference

9 August 2017

Leo ten Kate

2

1 reference

9 August 2017

Gerry Evers-Kiebooms

series ordinal

3

1 reference

9 August 2017

publication date

1 December 2003

1 reference

European Journal of Human Genetics

9 August 2017

published in

1 reference

9 August 2017

volume

11 Suppl 2

1 reference

9 August 2017

page(s)

S49-87

1 reference

Appraising organised screening programmes for testing for genetic susceptibility to cancer

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Genetic screening: a comparative analysis of three recent reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Gaining informed consent for screening. Is difficult--but many misconceptions need to be undone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Carrier screening for cystic fibrosis in a prenatal setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Participation in preconceptional carrier couple screening: characteristics, attitudes, and knowledge of both partners

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Antenatal screening for Down's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Developments in laboratory techniques for prenatal diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Alpha-fetoprotein in the antenatal diagnosis of anencephaly and spina bifida

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Appropriate biochemical parameters in first-trimester screening for Down syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Towards informed decisions about prenatal testing: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

First-trimester ultrasound screening for chromosomal defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

First trimester screening for structural fetal abnormalities: nuchal translucency sonography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

First-trimester trisomy screening: nuchal translucency measurement training and quality assurance to correct and unify technique.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

First trimester ultrasound screening. Carries ethical and psychological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Prenatal diagnosis of genetic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

ESHRE preimplantation genetic diagnosis (PGD) consortium: data collection II (May 2000).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Recent advances and future developments in PGD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

In the light of preimplantation genetic diagnosis: some ethical issues in medical genetics revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Genetic screening of newborns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

U.S. newborn screening policy dilemmas for the twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Prenatal diagnosis and screening of the haemoglobinopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Neonatal screening for cystic fibrosis. Cystic fibrosis should be added to diseases sought in all newborn babies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Neonatal screening for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Screening for cystic fibrosis and its evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Costs, effects, and savings of screening for cystic fibrosis gene carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Cystic fibrosis screening in newborns: results from existing programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Newborn screening for Duchenne muscular dystrophy: a psychosocial study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Efficacy of cascade testing for fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Prenatal diagnosis of fragile X syndrome and the risk of expansion of a premutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Screening for fragile X syndrome: information needs for health planners

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

A strategy for fragile-X carrier screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Case finding for the fragile X syndrome and its consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Feasibility and acceptance of screening for fragile X mutations in low-risk pregnancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Genetic testing for familial hypercholesterolaemia: practical and ethical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Screening for familial hypercholesterolaemia. Effective, safe treatments and dna testing make screening attractive

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Collusion in doctor-patient communication. Patients rarely regret optimism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Cholesterol screening in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Will genetic testing for predisposition for disease result in fatalism? A qualitative study of parents responses to neonatal screening for familial hypercholesterolaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Genetic testing, screening, and counseling issues in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Molecular epidemiology of familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Getting insurance after genetic screening on familial hypercholesterolaemia; the need to educate both insurers and the public to increase adherence to national guidelines in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Strategies for early diagnosis of haemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Genetic hemochromatosis, a Celtic disease: is it now time for population screening?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Psychosocial impact of C282Y mutation testing for hemochromatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Population screening for haemochromatosis: a unifying analysis of published intervention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Hereditary hemochromatosis: gene discovery and its implications for population-based screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Hereditary haemochromatosis: to screen or not. Conditions for screening are not yet fulfilled

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Mutation screening for prenatal and presymptomatic diagnosis: cystic fibrosis and haemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Evaluation of a counselling protocol for predictive genetic testing for hereditary non-polyposis colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Application of population screening principles to genetic screening for adult-onset conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Screening for early colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Cancer control in susceptible groups: opportunities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Cancer genetics services in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Existence and quality of written antenatal screening policies in the United Kingdom: postal survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Informed choice in genetic screening for thalassaemia during pregnancy: audit from a national confidential inquiry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

A multidisciplinary approach for improving services in primary care: randomised controlled trial of screening for haemoglobin disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Preconceptional couple screening for cystic fibrosis carrier status: couples prefer full disclosure of test results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Estimating the efficacy and efficiency of cascade genetic screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Delivering genetic screening to the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Antenatal genetic testing and the right to remain in ignorance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Informed consent for maternal serum alpha-fetoprotein screening in an inner city population: how informed is it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Informed consent for clinical trials: in search of the "best" method

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Commercialization of BRCA1/2 testing: practitioner awareness and use of a new genetic test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Health policy and the new genetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Screening practices for mutations in the CFTR gene ABCC7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

An overview of clinical molecular genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Issues underlying the evaluation of screening programmes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Screening in general practice and primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Evaluating newborn screening programmes based on dried blood spots: future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Can decision analysis help us decide whether ultrasound screening for fetal anomalies is worth it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Disclosure of Duchenne muscular dystrophy after newborn screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Prenatal screening and genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Generic Consent for Genetic Screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

Investigation of maternal blood enriched for fetal cells: role in screening and diagnosis of fetal trisomies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Acceptance of neonatal genetic screening for hereditary hemochromatosis by informed parents.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Routine Ultrasound Scanning for Congenital Abnormalities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Routine Ultrasound Screening of Congenital Anomalies: An Overview of the European Experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in an unselected population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Screening for genetic diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Neonatal screening for cystic fibrosis. Early diagnosis is important to parents even if it makes little difference to outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Cystic fibrosis newborn screening: impact on reproductive behavior and implications for genetic counseling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Clinical implications of the hemochromatosis gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Analysis of the cost of population screening for haemochromatosis using biochemical and genetic markers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Screening for hereditary hemochromatosis: are DNA-based tests the answer?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Diagnosis and management of haemochromatosis since the discovery of the HFE gene: a European experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

The C282Y mutation does not shorten life span

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Screening for hemochromatosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Management of women at high genetic risk of ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Screening for cystic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Cystic fibrosis carrier population screening: a review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Genetic testing and screening: the developing European jurisprudence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Cascade testing for the identification of carriers of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Population screening for cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Risk perception after CF carrier testing and impact of the test result on reproductive decision making

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Prenatal screening for cystic fibrosis carriers: does the method of testing affect the longer-term understanding and reproductive behaviour of women?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Understanding informed consent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

The commercialization of human genetics: profits and problems

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

The use and interpretation of commercial APC gene testing for familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Direct marketing of cystic fibrosis carrier screening: commercial push or population need?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Euroscreen 2: towards community policy on insurance, commercialization and public awareness

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Evaluation of CFTR gene mutation testing methods in 136 diagnostic laboratories: report of a large European external quality assessment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

MULTISCAN--a Scandinavian multicenter second trimester obstetric ultrasound and serum screening study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Integrated screening for Down's syndrome based on tests performed during the first and second trimesters

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

State-to-state variations in newborn screening policies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Population screening in the NHS: a systematic pathway from evidence to policy formulation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Convention for Protection of Human Rights and Dignity of the Human Being with Regard to the Application of Biology and Biomedicine: Convention of Human Rights and Biomedicine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EJHG.5201113

7 January 2021

Identifiers

DOI

10.1038/SJ.EJHG.5201113

1 reference

9 August 2017

1 reference